Neil Brewis - Mar 31, 2022 Form 4 Insider Report for F-star Therapeutics, Inc. (FSTX)

Role
Chief Scientific Officer
Signature
/s/ Darlene Deptula-Hicks, Attorney-in-fact
Stock symbol
FSTX
Transactions as of
Mar 31, 2022
Transactions value $
$0
Form type
4
Date filed
4/4/2022, 04:02 PM
Previous filing
Jan 11, 2022
Next filing
Aug 2, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FSTX Stock Option (right to buy) Award $0 +132K $0.00 132K Mar 31, 2022 Common Stock 132K $3.55 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These options were granted under the Issuer's 2019 Equity Incentive Plan.
F2 Twenty five percent (25%) of the total number of shares under the award shall vest on the first anniversary of the Vesting Commencement Date, March 31, 2022, and thereafter in 36 equal monthly installments such that the stock option shall be fully-vested on the fourth anniversary of the Vesting Commencement Date.